Mayo Clinic-Led Study Finds No Improvement in Overall Survival From Longer Multiple Myeloma Maintenance Therapy

Extended myeloma maintenance therapy shows no additional survival benefit

A major national cooperative group clinical trial led by Mayo Clinic researchers found that continuing maintenance therapy with lenalidomide

Stopping myeloma maintenance after two years shows no survival loss in trial

For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance ha

Trial Questions Continuous Maintenance in Newly Diagnosed Myeloma

(MedPage Today) -- Maintenance therapy with continuous lenalidomide (Revlimid) did not significantly improve overall survival (OS) in patien

Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance Therapy

STUDIO CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Study results from the randomized, prospective phase III ENDURANCE (E1A11) trial, des

Vincent Rajkumar: A 15-Year Marathon from Protocol to Paper in Multiple Myeloma

Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, shared on X: “Just out! In NEJM – Our randomized trial in myeloma (

<![CDATA[Shifting the Paradigm: Evidence, Earlier Use, and Sequencing of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma]]>